DCN Dx’s Clinical Research Helps Secure FDA Authorization for Cepheid HCV Test

Clinical Research Efforts Supported by NIH-FDA’s ITAP Program and Facilitate De Novo Authorization CARLSBAD, Calif., July 10, 2024 /PRNewswire/ — DCN Dx, a global leader in IVD CDMO and CRO services, is proud to amplify the news that the U.S. Food and Drug Administration (FDA) has…